RT Journal Article
SR Electronic
T1 Comparison of the Immunogenicity of five COVID-19 vaccines in Sri Lanka
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.15.21267834
DO 10.1101/2021.12.15.21267834
A1 Jeewandara, Chandima
A1 Aberathna, Inoka Sepali
A1 Danasekara, Saubhagya
A1 Gomes, Laksiri
A1 Fernando, Suranga
A1 Guruge, Dinuka
A1 Ranasinghe, Thushali
A1 Gunasekera, Banuri
A1 Kamaladasa, Achala
A1 Kuruppu, Heshan
A1 Somathilake, Gayasha
A1 Jayamali, Jeewantha
A1 Jayathilaka, Deshni
A1 Wijayatilake, Helanka Dinesh Kumara
A1 Pushpakumara, Pradeep Darshana
A1 Harvie, Michael
A1 Nimasha, Thashmi
A1 de Silva, Shiromi Devika Grace
A1 Wijayamuni, Ruwan
A1 Schimanski, Lisa
A1 Rijal, Pramila
A1 Tan, Jack
A1 Townsend, Alain
A1 Ogg, Graham S.
A1 Malavige, Gathsaurie Neelika
YR 2021
UL http://medrxiv.org/content/early/2021/12/15/2021.12.15.21267834.abstract
AB We assessed antibody responses 3 months post-vaccination in those who received mRNA-1273 (n=225), Sputnik V (n=128) or the first dose of Gam-COVID-Vac (n=184) and compared the results with previously reported data of Sinopharm and AZD1222 vaccinees. 99.5% of Moderna >94% of AZD1222 or Sputnik V, 72% to 76% of Gam-COVID-Vac (first dose) and 38.1% to 68.3% of Sinopharm vaccinees had ACE2 blocking antibodies above the positive threshold. The ACE2 blocking antibody levels were highest to lowest was Moderna > Sputnik V/ AZD1222 (had equal levels)> first dose of Gam-COVID-Vac > Sinopharm. All Moderna recipients had antibodies above the positive threshold to the ancestral (WT), B.1.1.7, B.1.351.1 and 80% positivity rate for B.1.617.2. Positivity rates of Sputnik V vaccinees for WT and variants, were higher than AZD1222 vaccinees, while Sinopharm vaccinees had the lowest positivity rates (<16.7%). These findings highlight the need for further studies to understand the effects on clinical outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are grateful to the Allergy, Immunology and Cell Biology Unit, University of Sri Jayewardenepura; the NIH, USA (grant number 5U01AI151788-02), UK Medical Research Council and the Foreign and Commonwealth Office for support. T.K.T. is funded by the Townsend-Jeantet Charitable Trust (charity number 1011770) and the EPA Cephalosporin Early Career Researcher Fund. A.T. are funded by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant no. 2018-I2M-2-002).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the Ethics Review Committee of University of Sri Jayewardenepura.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.